एपीए उद्धरण

Starr, P. (2015). Nivolumab Beats Docetaxel as Second-Line Therapy for Patients with NSCLC. Am Health Drug Benefits.

शिकागो स्टाइल उद्धरण

Starr, Phoebe. "Nivolumab Beats Docetaxel As Second-Line Therapy for Patients With NSCLC." Am Health Drug Benefits 2015.

एमएलए उद्धरण

Starr, Phoebe. "Nivolumab Beats Docetaxel As Second-Line Therapy for Patients With NSCLC." Am Health Drug Benefits 2015.